Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 1;25(4):250-256.
doi: 10.34172/aim.2022.41.

Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women

Lobna Bouzidi  1   2 , Saadia Makni  1   2 , Jihen Feki  3 , Rim Kallel  1   2 , Soumaya Graja  1   2 , Naourez Gouiaa  1   2 , Tahya Sellami-Boudawara  1   2 , Manel Mellouli  1   2
Affiliations

Immunohistochemical Overexpression of Cyclin D1 in Tunisian Invasive Breast Carcinoma Women

Lobna Bouzidi et al. Arch Iran Med. .

Abstract

Background: Breast cancer represents the most frequent cancer and cause of death in women worldwide and in Tunisia. Cyclin D1 is a gene of cell cycle regulation. It represents a potential oncogene in invasive breast cancer; however; the results are conflicting. We performed a retrospective study aiming to analyze the prognostic impact of cyclin D1 expression in patients with invasive breast carcinoma of no special type and its relation with clinical-pathological features.

Methods: One hundred cases of invasive breast carcinoma of no special type diagnosed between 2009 and 2011 were included in this study. Immunohistochemical (IHC) staining was performed for cyclin D1 in all cases. Results were analyzed statistically.

Results: Cyclin D1 positivity was seen in 74 cases (74%), of which 32 cases (32%) showed strong immunoreactivity. Cyclin D1 staining was statistically significantly associated with estrogen receptor (ER) and progesterone receptor (PR) positivity (P<0.0001) and with low grade SBR (P=0.007). None of the clinical data and other pathological features had any association with cyclin D1 expression (P>0.05). Univariate analysis revealed that expression of cyclin D1 was not statistically associated with overall survival (OS) and disease-free survival (DFS) (P=0.459 and P=0.564, respectively).

Conclusion: These results confirm that cyclin D1 overexpression can be employed as a beneficial prognostic marker and suggest that anti-cyclin D1 therapy may be efficient, especially for ER positive tumors.

Keywords: Breast cancer; Cyclin D1; Estrogen receptor; Progesterone receptor; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures

The authors declare that they have no conflict of interest

Figures

Figure 1
Figure 1
Figure 2
Figure 2
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Ravikumar G, Ananthamurthy A. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. J Cancer Res Ther. 2014;10(3):671–5. doi: 10.4103/0973-1482.138135. - DOI - PubMed
    1. Galant C, Berlière M, Leconte I, Marbaix E. Overview of histopathological prognostic factors in breast cancer, including newcomers. Imagerie de la Femme. 2010;20(1):9–17. doi: 10.1016/j.femme.2010.02.002. - DOI
    1. Dialla PO, Dabakuyo TS, Marilier S, Gentil J, Roignot P, Darut-Jouve A. et al. Population-based study of breast cancer in older women: prognostic factors of relative survival and predictors of treatment. BMC Cancer. 2012;12:472. doi: 10.1186/1471-2407-12-472. - DOI - PMC - PubMed
    1. Dabakuyo TS, Bonnetain F, Roignot P, Poillot ML, Chaplain G, Altwegg T. et al. Population-based study of breast cancer survival in Cote d’Or (France): prognostic factors and relative survival. Ann Oncol. 2008;19(2):276–83. doi: 10.1093/annonc/mdm491. - DOI - PubMed